Comparison of prolactin level, sexual function, body mass index, and liver function tests in patients using depot antipsychotics
Abstract
Purpose: In this study, it was aimed to compare sexual dysfunctions, body mass index, liver function tests and prolactin levels in patients using long-acting antipsychotic drug forms (depot paliperidone palmitate, risperidone depot and zuclopenthixol depot).
Materials and Methods: Patients diagnosed with schizophrenia and receiving long-acting antipsychotic therapy were included in this study. Demographic data form, Positive and Negative Syndrome Scale (PANSS), Calgary Depression in Schizophrenia Scale (CDSS), and Arizona Sexual Experiences Scale (ASEX) were administered to all participants. Venous blood samples were obtained from all participants to evaluate urea, creatinine, liver function tests, cholesterol and prolactin levels.
Results: 95 patients were included in the study. Of those included, 79 (83.2%) were men and 16 (16.8%) were women. The mean age of all patients was 36.77±10.24 years. The mean body mass index was 27.06±4.95 kg/m2. There was no difference between the groups in terms of ASEX and CDSS scores. The prolactin level was found to be higher in patients using paliperidone depot than in patients using zuclopenthixol depot.
Conclusion: According to our results, prolactin values that affect sexual functions should be considered in patients using long-acting antipsychotics, even if the patients do not show any symptoms. Further researches should be conducted on the effects of long-acting antipsychotic use on both prolactin values and other laboratory parameters.
Keywords
Long-acting antipsychotic drugs , sexual function , prolactin , liver function tests
Kaynakça
- 1. Öztürk O, Uluşahin N. Ruh Sağlığı ve Bozuklukları. 13. Baskı. Ankara: Nobel Tıp Kitapevi; 2015. p.189-261.
- 2. Gaebel W, Zielasek J. Schizophrenia in 2020: Trends in diagnosis and therapy. Psychiatry Clin Neurosci. 2015; 69(11): 661-673.
- 3. Sacchetti E, Grunze H, Leucht S, Vita A. Longacting injection antipsychotic medications in the management of schizophrenia. Evidence-based Psychiatric Care. 2015;1:27-36.
- 4. Miyamoto S, Wolfgang Fleischhacker W. The use of long-acting injectable antipsychotics in schizophrenia. Curr Treat Options Psychiatry. 2017;4:117-26. 5. Olivares JM, Pinal B, Cinos C. Comparisons of long-acting antipsychotics injection and oral antipsychotics in schizophrenia. Neuropsychiatry. 2011;1:275-89.
- 6. Lingjærde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychatr Scand. 1987;76(334).
- 7. Adams CE, Fenton MK, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry. 2001;179:290-99.
- 8. İnanç L, Özdemir AD, Güleç H, Semiz ÜB. Şizofreni ve bipolar bozukluk hastalarında depo antipsikotik kullanmanın etkinliği ve güvenirliği. Cukurova Med J. 2018; 43(Ek 1): 38-43.
- 9. Montejo AL, Majadas S, Rico-Villademoros F, LLorca G, De La Gándara J, Franco M, et al. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. Frequency of sexual dysfunction in patients with a psychotic disorder receiving antipsychotics. J Sexual Med. 2010; 7(10), 3404-3413.
- 10. Montejo AL, Montejo L, Baldwin DS. The impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management. World Psychiatry, 2018; 17(1): 3-11.
- 11. Aykut DS. Comparison of paliperidone palmitate and second-generation oral antipsychotics in terms of medication adherence, side effects, and quality of life. J Clin Psychopharmacol. 2019; 39(1): 57-62.
